Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
https://ir.celcuity.com/news-releases/news-re...y-endpoint
I don't think this constitutes competition for us, but maybe ohm20 could chime in and elaborate on this press release.